🔍

JUBLPHARMA - Jubilant Pharmo

📊 NSE: JUBLPHARMA 🏢 Pharmaceuticals - Indian - Bulk Drugs 📅 Last Updated: 12/14/2025 8:43

📢 Recent Corporate Announcements

Jubilant Pharmova's Montreal Facility Receives USFDA OAI Classification

🔴 NEGATIVE ⭐ 7/10

REGULATORY 📅 13 Feb 2026, 11:10 PM

Jubilant Pharmova's contract manufacturing facility in Montreal, Canada (CMO Montreal), has received an 'Official Action Indicated' (OAI) classification from the USFDA following an audit conducted in October and November 2025. An OAI status typically implies that the regulator may withhold approvals for new products from the site until issues are resolved. However, the company has already implemented remediation measures and resumed production operations at the facility in Q4'FY26. The company continues to work closely with the USFDA to address the specific audit observations.

USFDA classifies CMO Montreal facility as Official Action Indicated (OAI) following late 2025 audit
Production operations at the site have successfully resumed in Q4'FY26 after remediation efforts
The facility is a strategic alliance under Jubilant HollisterStier, focusing on sterile injectables and ophthalmics
Jubilant Pharmova is working with the USFDA to resolve all outstanding regulatory observations

💡 Investors should monitor the timeline for the USFDA to upgrade the facility's status from OAI, as this classification can delay new product launches. While the resumption of production is a positive operational step, the regulatory risk remains until a successful re-inspection or close-out letter is received.

Jubilant Pharmova Q3 Revenue Rises 17% to Rs 2,123 Cr; CDMO Growth Offsets Montreal Shutdown

🔵 WATCH ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 12:48 PM

Jubilant Pharmova reported a solid 17% YoY revenue growth in Q3 FY26, reaching Rs 2,123 crore, driven by a 49% surge in the CDMO Sterile Injectables segment. However, normalized PAT declined by 17% to Rs 86 crore, and EBITDA margins contracted to 14.5% due to a temporary remediation-related shutdown at the Montreal facility. The company's leverage improved with Net Debt/EBITDA falling to 1.3x from 1.5x in the previous quarter. Management expects margin recovery in Q4 as production has resumed at the Montreal site and new capacities ramp up.

Revenue grew 17% YoY to Rs 2,123 Cr, while 9M FY26 revenue reached Rs 5,990 Cr (up 13%).
CDMO Sterile Injectables revenue jumped 49% YoY to Rs 457 Cr, supported by the new Line 3 in Spokane.
EBITDA margins contracted by 172 bps YoY to 14.5% due to Montreal facility shutdown and remediation costs.
Ruby-Fill installation base grew by 37% in 9M FY26, significantly outpacing the 21% growth in FY25.
Generics business remained profitable for the third consecutive quarter with 13% revenue growth.

💡 Investors should focus on the margin recovery trajectory in Q4 as the Montreal facility resumes operations and high-margin Radiopharma products scale. The strong top-line growth in CDMO and Radiopharma provides a positive long-term outlook despite temporary operational headwinds.

Jubilant Pharmova Q3 Standalone Net Profit Rises 24.5% YoY to ₹66 Million

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 12:40 PM

Jubilant Pharmova reported a 20% YoY growth in standalone revenue to ₹673 million for the quarter ended December 31, 2025. Profit before tax from continuing operations saw a significant surge of 90% YoY, reaching ₹101 million, primarily driven by a sharp reduction in finance costs. The company successfully completed the slump sale of its API business to its subsidiary, Jubilant Biosys, on September 1, 2025, which is now reflected as discontinued operations. Total net profit for the quarter stood at ₹66 million, up from ₹53 million in the corresponding quarter of the previous year.

Standalone revenue from operations increased 20% YoY to ₹673 million in Q3 FY26.
Profit before tax from continuing operations surged 90% YoY to ₹101 million.
Finance costs significantly decreased to ₹9 million from ₹33 million in the year-ago period.
The API business transfer was completed for a net asset value of ₹5,956 million on September 1, 2025.
Total comprehensive income for the period stood at ₹67 million versus ₹51 million YoY.

💡 Investors should view the sharp reduction in finance costs and the restructuring of the API business as positive steps toward operational efficiency. Monitor the consolidated results for a clearer picture of the group's overall growth trajectory post-restructuring.

Jubilant Pharmova to Meet 29 Institutional Investors at Nuvama Conference on Feb 9

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 02 Feb 2026, 09:46 PM

Jubilant Pharmova has scheduled physical meetings with 29 major institutional investors on February 9, 2026, in Mumbai. The list includes high-profile entities such as Abu Dhabi Investment Authority, Goldman Sachs Asset Management, and HDFC Life Insurance. These meetings, organized by Nuvama Institutional Equities, will focus on the company's Q3 FY26 earnings. The financial results for the quarter are slated for disclosure on February 6, 2026, just prior to these meetings.

Scheduled meetings with 29 institutional investors including ADIA, Fidelity, and Goldman Sachs
Meetings to be held on February 9, 2026, as part of the Nuvama India Conference 2026
Discussions will center on Q3 FY26 earnings presentation following the Feb 6 results release
Broad participation from domestic funds like ICICI Prudential, HDFC Life, and Invesco Mutual Fund

💡 Investors should focus on the Q3 FY26 financial results to be released on February 6, as these will form the basis of institutional discussions. The high level of institutional interest suggests a need to watch for potential post-result volatility.

Jubilant Pharmova to Meet 29 Institutional Investors at Nuvama Conference on Feb 9, 2026

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 02 Feb 2026, 09:43 PM

Jubilant Pharmova has scheduled physical meetings with 29 major institutional investors on February 9, 2026, in Mumbai. The meetings, organized by Nuvama Institutional Equities, include marquee names such as Abu Dhabi Investment Authority, Goldman Sachs, and HDFC Life. Management will discuss the Q3 FY26 earnings, which are scheduled to be released on February 6, 2026. This high level of institutional engagement indicates significant market interest in the company's upcoming financial results and strategic outlook.

Management to meet 29 institutional investors physically in Mumbai on February 9, 2026.
Key participants include Abu Dhabi Investment Authority, Goldman Sachs Asset Management, and ICICI Prudential AMC.
Meetings are part of the Nuvama India Conference 2026.
Discussions will focus on Q3 FY26 earnings presentation following the official disclosure on February 6, 2026.

💡 Investors should focus on the Q3 FY26 financial results to be released on February 6, as these will form the basis of the institutional discussions. The strong interest from global and domestic funds is a positive sentiment indicator but does not change immediate fundamentals.

Jubilant Pharmova Submits SEBI Compliance Certificate for Q3 FY2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 07:09 PM

Jubilant Pharmova Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Alankit Assignments Limited, confirms the processing of dematerialization requests for the quarter ended December 31, 2025. It verifies that physical share certificates received were duly cancelled and the depository's name was updated in the records. This filing is a standard administrative requirement to ensure the integrity of the company's shareholding data.

Compliance certificate submitted for the quarter ended December 31, 2025
Issued by Registrar and Share Transfer Agent, M/s Alankit Assignments Limited
Confirms that dematerialized securities are listed on the BSE and NSE
Confirms physical certificates were mutilated and cancelled after verification
Ensures adherence to SEBI (Depositories and Participants) Regulations, 2018

💡 No action is required from investors as this is a routine regulatory filing. Focus should remain on the company's operational performance and upcoming financial results.

Jubilant Pharmova Reports Nil Requests in Special Window for Physical Share Transfers

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 02 Jan 2026, 06:18 PM

Jubilant Pharmova has submitted a regulatory update regarding the special window for re-lodgement of physical share transfer requests as of December 31, 2025. This filing is in compliance with SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97. The company's Registrar and Share Transfer Agent, Alankit Assignments Limited, reported that zero requests were received or processed during the month. This is a standard administrative disclosure with no impact on the company's financial performance.

Zero (Nil) requests received for re-lodgement of physical share transfers during the month ending December 31, 2025.
Zero (Nil) requests were processed, approved, or rejected by the Registrar, Alankit Assignments Limited.
Compliance filing follows the SEBI Circular dated July 2, 2025, regarding physical share transfer mechanisms.
The report confirms the status of the special window as of the end of the 2025 calendar year.

💡 No action is required for the majority of investors. Shareholders still holding physical certificates are encouraged to dematerialize their holdings for easier liquidity and compliance.

Jubilant Pharmova Receives Rs 22.10 Crore Income Tax Demand for FY 2020

🔵 WATCH ⭐ 4/10

LEGAL 📅 31 Dec 2025, 12:56 PM

Jubilant Pharmova Limited has received a tax demand order of Rs 22.10 crore from the Income Tax Department for the financial year 2020. The demand is primarily attributed to arithmetical errors, transfer pricing adjustments, and disallowance of certain expenses. The company believes the order contains mistakes apparent from the records and has ignored their previous contentions. Management plans to file a rectification application or appeal, expecting the demand to be deleted without material financial impact.

Tax demand of Rs 22.10 crore raised by the Income Tax Department, Moradabad for FY 2020.
Issues cited include arithmetical errors, transfer pricing adjustments, and expense disallowances.
Company intends to file a rectification application and/or an appeal before the ITAT.
Management expects the demand to be vacated and does not anticipate material financial implications.
The order was received by the company on December 30, 2025.

💡 Investors should monitor the outcome of the rectification or appeal process. Given the company's stance on arithmetical errors, this is likely a routine tax dispute with limited immediate risk to the stock.

Jubilant Pharmova acquires 100% stake in Canadian entity for CAD 30,000

🟡 NEUTRAL ⭐ 4/10

M&A 📅 30 Dec 2025, 05:49 PM

Jubilant Pharmova's subsidiary, Jubilant Generics Limited, has acquired a 100% stake in Jubilant Pharmaceuticals Inc., Canada, for a cash consideration of CAD 30,000 (approximately INR 0.20 crores). The target entity is a newly incorporated company (June 2025) that has not yet commenced business operations and currently reports nil turnover. This acquisition is a strategic move to establish a branded generic business and strengthen the company's presence in the Canadian market. While the financial outlay is minimal, it sets the foundation for future revenue growth in North America.

Acquisition of 100% shareholding (30,000 shares) in Jubilant Pharmaceuticals Inc., Canada.
Total investment cost is CAD 30,000, which is approximately INR 0.20 crores.
Target entity was incorporated on June 17, 2025, and has zero turnover to date.
Strategic objective is to establish a branded generic business and expand Canadian market presence.

💡 The investment is negligible relative to the company's size, so no immediate action is required. Investors should treat this as a routine structural setup for future international expansion.

Jubilant Pharmova to Close Trading Window from Jan 1, 2026, for Q3 FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Dec 2025, 03:49 PM

Jubilant Pharmova Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is a standard procedure ahead of the declaration of the company's unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025. The window will remain closed for all designated persons until 48 hours after the results are officially announced to the stock exchanges. The specific date for the board meeting to approve these results will be communicated in due course.

Trading window closure effective from Thursday, January 1, 2026.
Closure pertains to the financial results for the quarter and nine months ending December 31, 2025.
Window will reopen 48 hours after the financial results are disclosed to BSE and NSE.
Designated persons and insiders are prohibited from trading in company securities during this period.

💡 This is a routine regulatory filing with no immediate impact on stock fundamentals; investors should monitor for the upcoming board meeting date to assess Q3 performance.

Jubilant Pharmova Subsidiary Receives GST Demand and Penalty of ₹1.73 Crore

🟡 NEUTRAL ⭐ 3/10

LEGAL 📅 27 Dec 2025, 12:08 PM

Jubilant Pharmova's wholly-owned subsidiary, Jubilant Generics Limited, has received a GST demand order from the Assistant Commissioner Central GST Division, Roorkee. The order seeks the recovery of an erroneously sanctioned provisional refund amounting to ₹1.57 crore plus a penalty of ₹15.68 lakh. The total financial implication of the order is approximately ₹1.73 crore. The company maintains that the demand is legally incorrect and intends to file an appeal before the Commissioner (Appeals).

Total GST demand and penalty amount to ₹1,72,50,923.
The demand includes a base GST claim of ₹1,56,82,657 and a penalty of ₹15,68,266.
The dispute involves an alleged incorrect calculation of a previously sanctioned provisional refund.
Management states there is no material impact on the company's financials or operations.
The company plans to contest the order before the Commissioner (Appeals) based on legal merits.

💡 This is a minor tax litigation matter with low financial impact relative to the company's size. Investors should treat this as a routine regulatory update and no immediate action is required.

Jubilant Pharmova Subsidiary Receives ₹9.71 Crore GST Demand and Penalty

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 25 Dec 2025, 06:52 PM

Jubilant Pharmova's wholly-owned subsidiary, Jubilant Biosys Limited, has received a GST demand order totaling ₹9.71 crore from the Joint Commissioner Noida. The order includes a GST demand of ₹6.98 crore and a penalty of ₹2.72 crore for the financial years 2020-21 to 2022-23. The dispute relates to alleged discrepancies in the availment of Input Tax Credit (ITC). The company maintains that the demand is legally incorrect and plans to file an appeal, stating there is no material impact on its financials or operations.

Total financial implication of ₹9.71 crore, comprising ₹6.98 crore tax and ₹2.72 crore penalty
Demand covers a three-year period from FY 2020-21 to FY 2022-23
Primary issue involves alleged discrepancies in Input Tax Credit (ITC) claims
Company to file an appeal before the Commissioner (Appeals) to contest the order
Management confirms no material impact on the company's overall operations or financials

💡 Investors should treat this as a routine tax dispute; the quantum of the demand is not significant enough to impact the company's valuation. Monitor for any further escalations in tax-related litigation.

Jubilant Pharmova appoints Daniel J. O’Connor as CEO of Jubilant Therapeutics Inc.

🟡 NEUTRAL ⭐ 5/10

MANAGEMENT 📅 02 Dec 2025, 05:28 PM

Jubilant Pharmova Limited announced the appointment of Mr. Daniel J. O’Connor as CEO of Jubilant Therapeutics Inc., a step-down subsidiary. Mr. O'Connor brings over 30 years of experience in Biotechnology and Oncology. He previously served as CEO of Ambrx Biopharma, where he drove a significant increase in company valuation leading to its acquisition. Jubilant Therapeutics is focused on developing innovative therapies across multiple cancer indications.

Daniel J. O’Connor appointed as CEO of Jubilant Therapeutics Inc.
Daniel J. O’Connor has more than 30 years of leadership experience.
Jubilant Therapeutics Inc. is in Phase I/II clinical trial in multiple tumors with JBI-802.

💡 Investors should monitor the progress of Jubilant Therapeutics' clinical trials and any strategic collaborations. Keep an eye on how this leadership change impacts the development of new therapies.

Jubilant Pharmova appoints Daniel J. O’Connor as CEO of Jubilant Therapeutics Inc.

🟡 NEUTRAL ⭐ 5/10

MANAGEMENT 📅 02 Dec 2025, 08:45 AM

Jubilant Pharmova Limited announced the appointment of Mr. Daniel J. O’Connor as CEO of Jubilant Therapeutics Inc., a step-down subsidiary. Mr. O'Connor brings over 30 years of experience in Biotechnology and Oncology. Previously, he served as CEO of Ambrx Biopharma, leading to a significant increase in company valuation and its subsequent acquisition. He also contributed to the development of a major oncology therapy at ImClone Systems. Jubilant Therapeutics is focused on developing innovative therapies across multiple cancer indications.

Daniel J. O’Connor appointed as CEO of Jubilant Therapeutics Inc.
Daniel J. O’Connor has over 30 years of leadership experience in Biotechnology and Oncology.
Jubilant Therapeutics Inc. is a clinical stage biopharmaceutical company.
Jubilant Therapeutics Inc. is developing precision oral medicines for oncology and autoimmune diseases.

💡 Investors should monitor the performance of Jubilant Therapeutics under the new CEO, focusing on the progress of its clinical pipeline and strategic collaborations. Keep an eye on news related to JBI-802 and the novel brain-penetrant modulator of PRMT5.

View All JUBLPHARMA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue for Q2'FY26 grew 12% YoY to INR 1,966 Cr, driven by the new third line in CDMO Sterile Injectables and growth in Radiopharma, Allergy Immunotherapy, and CRDMO. In FY25, CDMO Sterile Injectables EBITDA grew 52% with margins expanding from 17.2% to 23.0%, while CRDMO EBITDA rose 32.3% with margins improving from 15.5% to 19.4%.

Geographic Revenue Split

The US market is the primary revenue driver, contributing 82% of total revenue in H1'FY26. The origin of goods sold in the US is 72% from the US, 17% from Canada, and 12% from India.

Profitability Margins

Normalised PAT Margin for Q2'FY26 stood at 6.3%, an improvement of 50 bps YoY. For H1'FY26, the Normalised PAT margin was 5.8%, up 96 bps YoY. FY25 Consolidated Net Profit surged to INR 836.3 Cr from INR 72.7 Cr in FY24, reflecting a substantial turnaround in the Generics segment and operational excellence.

EBITDA Margin

EBITDA margin for Q2'FY26 was 17.8%, reflecting a 24 bps YoY increase. H1'FY26 EBITDA margin was 16.8%, up 40 bps YoY. Consolidated EBITDA for FY25 was INR 1,230.5 Cr, a 26.9% increase over FY24.

Capital Expenditure

The company is executing a CAD 145 million (approx. INR 900 Cr) modernization and capacity expansion project in Montreal to double sterile production capacity. Additionally, revenue generation has commenced from the new third line at the Spokane, US facility in Q2'FY26.

Credit Rating & Borrowing

The company has outstanding Secured Redeemable Unlisted Non-Convertible Debentures (NCDs) of INR 70 Cr as of March 31, 2025, with the tenure extended by five years. Finance costs were reduced in H1'FY26, contributing to a 32% YoY increase in Normalised PAT to INR 227 Cr.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (API), sterile fill-finish components, and chemicals for radiopharmaceuticals. The API business reported revenue of INR 137 Cr in Q2'FY26, up 8% YoY.

Import Sources

Sourcing is diversified across the US (72% of US sales origin), Canada (17%), and India (12%), with a 'China plus one' strategy implemented to increase backward integration and supplier resilience.

Key Suppliers

Not specifically named in the documents, but the company utilizes select Contract Manufacturing Organisations (CMOs) for its Generics business and maintains a diversified supplier base for its API segment.

Capacity Expansion

CDMO Sterile Injectables: New third line at Spokane, US is now operational. Montreal, Canada: CAD 145 million project to double sterile production capacity is expected to be operational in H2 FY26.

Raw Material Costs

Total operating expenditure for FY25 was INR 6,060.8 Cr on a consolidated basis, representing approximately 83.7% of revenue. The company focuses on cost optimization and improved revenue mix toward high-margin custom manufacturing.

Manufacturing Efficiency

The Generics segment transitioned from in-house manufacturing to a CMO-based model to focus on profitable product lines and margin enhancement. CDMO API asset utilization is being increased by shifting the mix toward custom manufacturing.

Logistics & Distribution

The company maintains a strong sales and marketing presence in the US, leveraging products from its India facility and CMOs to serve major wholesalers and retail chains.

📈 Strategic Growth

Expected Growth Rate

11%

Growth Strategy

Growth will be achieved through the ramp-up of the new third line in Spokane, doubling capacity in Montreal by H2 FY26, and scaling contracts with three new large pharmaceutical companies onboarded in the last year. The company is also exploring monetization of its Proprietary Novel Drugs (JBI-802, JBI-778) through licensing or external fundraising following clinical data readouts in CY 2026.

Products & Services

Radiopharmaceuticals, Allergy Immunotherapy, Sterile Injectables (CDMO), Solid Dosage Formulations (Generics), Drug Discovery Services (CRDMO), and Proprietary Novel Drugs for oncology.

Brand Portfolio

Jubilant Biosys, Jubilant HollisterStier, Jubilant Cadista, Draximage, and Jubilant Therapeutics.

New Products/Services

Proprietary Novel Drugs JBI-802 and JBI-778 are in clinical trials; JBI-2174 has launched a Phase I first-in-human study for cancer sub-sets in India.

Market Expansion

Expansion into new geographies for existing products and increasing partnerships with large pharma companies to leverage expanded infrastructure in India and North America.

Market Share & Ranking

Recognized as a 'Partner of Choice' by leading global pharmaceutical companies; Jubilant HollisterStier is a leading global CMO in sterile fill-finish.

Strategic Alliances

Partnership with the Government of Canada (Strategic Innovation Fund) providing CAD 23.8 million and the Province of Quebec providing CAD 25 million for capacity expansion.

🌍 External Factors

Industry Trends

The industry is shifting toward outsourced sterile manufacturing and specialized drug discovery. Jubilant is positioning itself by doubling sterile capacity and integrating API with drug discovery services.

Competitive Landscape

Competes with global CDMOs and generic manufacturers; competitive advantage is derived from a diversified portfolio and manufacturing presence in North America.

Competitive Moat

Moat is sustained by high regulatory barriers (US FDA/international compliance), specialized manufacturing capabilities in Radiopharma and Allergy, and long-term 'Partner of Choice' relationships with large pharma.

Macro Economic Sensitivity

Sensitive to US healthcare spending and biotech funding environments; softening demand in the biotech sector was noted due to uncertain economic conditions.

Consumer Behavior

Increased end-user awareness of cybersecurity risks and a shift toward specialized oncology treatments are driving demand for the company's novel drug pipeline.

Geopolitical Risks

The proposed US Biosecure Act is expected to drive 'friend-shoring' demand toward Indian CROs, benefiting Jubilant's CRDMO business.

⚖️ Regulatory & Governance

Industry Regulations

Strict adherence to US FDA current Good Manufacturing Practices (cGMP) and Regulation 24A of SEBI Listing Regulations for material subsidiaries.

Environmental Compliance

The company maintains an Enterprise Risk Management program and ESG training for personnel to comply with changing global standards.

Taxation Policy Impact

Effective tax rate for Q2'FY26 was abnormally higher due to a one-time net tax expense of INR 13 Cr related to the slump sale of the API business.

Legal Contingencies

Jubilant Biosys Limited received an Adjudication Order for GST, interest, and penalty for FY 2021-22; the company is contesting this before the GST Appellate Authority and expects no financial impact.